Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.016
Buy
RSI(14)
55.314
Neutral
STOCH(KDJ)(9,3,3)
79.740
Neutral
ATR(14)
0.418
High Vlolatility
CCI(14)
61.633
Neutral
Williams %R
19.598
Overbought
TRIX(12,20)
0.006
Sell
StochRSI(14)
38.602
Sell
Search
Xilio Therapeutics Inc
XLOAdd to Watchlist
9.110USD
+0.030+0.33%
Close 07-31 16:00（ET）Quotes delayed by 15 min
52.68MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.33%
5 Days
+5.32%
1 Month
-4.91%
6 Months
+9.38%
Year to Date
+1.64%
1 Year
+0.30%
Key Figures
9.000Open
9.160High
11.43KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.20%Turnover Ratio
9.080Prev. Close
8.890Low
44.05KTurnover
LossP/E Static
0.73P/B
0.00%Div Yield TTM
-23.43%ROA
16.10052wk High
0.50Volume Ratio
-58.24MNet Profit
5.78MShares
-56.7568EPS TTM
-0.10Beta
-75.20%ROE
6.46552wk Low
2.97%Amplitude
100.00%Gross Margin
52.68MMarket Cap
-1.20Reward/Risk
3.18%Risk Rate
TradingKey Stock Score of Xilio Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Xilio Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xilio Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Xilio Therapeutics Inc Highlights
StrengthsRisks
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.77M.
Overvalued
The company’s latest PE is -0.16, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
20.000
Target Price
+119.78%
Upside Space
Xilio Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
20.000
Target Price
+119.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Xilio Therapeutics Inc
XLO
1
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
9.106
Buy
MA10
8.824
Buy
MA20
8.993
Buy
MA50
8.707
Buy
MA100
8.420
Buy
MA200
8.925
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xilio Therapeutics Inc Info
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Ticker SymbolXLO
CompanyXilio Therapeutics Inc
CEORusso (Rene)
Websitehttps://xiliotx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Xilio Therapeutics Inc (XLO)?
The current price of Xilio Therapeutics Inc (XLO) is 9.10.
What is the symbol of Xilio Therapeutics Inc?
The ticker symbol of Xilio Therapeutics Inc is XLO.
What is the 52-week high of Xilio Therapeutics Inc?
The 52-week high of Xilio Therapeutics Inc is 16.10.
What is the 52-week low of Xilio Therapeutics Inc?
The 52-week low of Xilio Therapeutics Inc is 6.47.
What is the market capitalization of Xilio Therapeutics Inc?
The market capitalization of Xilio Therapeutics Inc is 52.62M.
Is Xilio Therapeutics Inc (XLO) currently rated as Buy, Hold, or Sell?
According to analysts, Xilio Therapeutics Inc (XLO) has an overall rating of STRONG BUY, with a price target of 20.00.
What is the Earnings Per Share (EPS TTM) of Xilio Therapeutics Inc (XLO)?
The Earnings Per Share (EPS TTM) of Xilio Therapeutics Inc (XLO) is -4.19.